Overview

IMM0306 in Combination With Lenalidomide VS Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-10-01

Target enrollment:

Participant gender:

Summary

This study is a randomized, controlled, double-blind, multicenter, phase III clinical study to evaluate the efficacy of IMM0306 Amouravfop Alfain combination with lenalidomide versus placebo in combination with lenalidomide in patients with Relapsed/Refractory Follicular lymphoma. Primary endpoints are Complete Remission Rate (CRR) and Progression-Free Survival (PFS).

Phase:

PHASE3

Details

Lead Sponsor:

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Treatments:

Lenalidomide